Panel Chosen to Judge SSC Bids

WASHINGTON—The National Academy of Sciences has assembled its blue-ribbon panel to assess proposals for the Superconducting Supercollider. And participants promise that the group will take a balanced—if not completely disinterested—look at the suitability of what are expected to be dozens of proposals to land the multibillion dollar construction and research project. "Short of getting Martians, there was no way to avoid bringing in people who might be affected by the ultimate

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

"Short of getting Martians, there was no way to avoid bringing in people who might be affected by the ultimate decision on sitting," asserted Bill Spindeil, an NAS staffer for the panel. "They can be an advocate for the SSC, but we made sure that no one on the panel is involved in any state's effort to submit a proposal."

Unless Congress decides to intervene, proposals are due by August 3 to the Department of Energy. After a preliminary screening to ensure that the submission meets mini mum eligibility standards, DOE officials will forward the proposals to a 20-member group chaired by Ed ward A. Frieman. The director of the Scripps Institute of Oceanography in La Jolla, Calif., Frieman is a former head of DOE's Office of Energy Research, which will oversee construction and operation of the SSC.

The panel has been asked to con duct a technical evaluation of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies